These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 34074809)
21. POTENTIAL LIFE PROGNOSTIC MARKER FOR MESENCHYMAL TUMOR RESEMBLING UTERINE LEIOMYOSARCOMA. Nishikawa S; Hayashi T; Uzaki T; Yaegashi N; Abiko K; Konishi I Georgian Med News; 2023 Oct; (343):119-126. PubMed ID: 38096528 [TBL] [Abstract][Full Text] [Related]
22. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039 [TBL] [Abstract][Full Text] [Related]
23. Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia. Oliva E Mod Pathol; 2016 Jan; 29 Suppl 1():S104-20. PubMed ID: 26715170 [TBL] [Abstract][Full Text] [Related]
24. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. O'Neill CJ; McBride HA; Connolly LE; McCluggage WG Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074 [TBL] [Abstract][Full Text] [Related]
26. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors. Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689 [TBL] [Abstract][Full Text] [Related]
27. Criteria for risk stratification of vulvar and vaginal smooth muscle tumors: a follow-up study with application to leiomyoma variants, smooth muscle tumors of uncertain malignant potential, and leiomyosarcomas. Swanson AA; Howitt BE; Schoolmeester JK Hum Pathol; 2020 Sep; 103():83-94. PubMed ID: 32687944 [TBL] [Abstract][Full Text] [Related]
28. Fascin expression in uterine smooth muscle tumors. Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633 [TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical analysis in the diagnosis of uterine myometrial smooth muscle tumors. Stănescu AD; Nistor E; Sajin M; Stepan AE Rom J Morphol Embryol; 2014; 55(3 Suppl):1129-36. PubMed ID: 25607395 [TBL] [Abstract][Full Text] [Related]
30. Leiomyoma With Bizarre Nuclei: Clinical and Pathologic Features of 30 Patients. Kefeli M; Caliskan S; Kurtoglu E; Yildiz L; Kokcu A Int J Gynecol Pathol; 2018 Jul; 37(4):379-387. PubMed ID: 28700441 [TBL] [Abstract][Full Text] [Related]
31. Differential diagnosis of uterine smooth muscle tumors using diffusion-weighted imaging: correlations with the apparent diffusion coefficient and cell density. Tasaki A; Asatani MO; Umezu H; Kashima K; Enomoto T; Yoshimura N; Aoyama H Abdom Imaging; 2015 Aug; 40(6):1742-52. PubMed ID: 25526683 [TBL] [Abstract][Full Text] [Related]
32. Mass lesions of the myometrium: interpretation and management of unexpected pathology. Porter AE; Kho KA; Gwin K Curr Opin Obstet Gynecol; 2019 Oct; 31(5):349-355. PubMed ID: 31425175 [TBL] [Abstract][Full Text] [Related]
33. EMMPRIN (CD147) Expression in Smooth Muscle Tumors of the Uterus. Kefeli M; Yildiz L; Gun S; Ozen FZ; Karagoz F Int J Gynecol Pathol; 2016 Jan; 35(1):1-7. PubMed ID: 26352545 [TBL] [Abstract][Full Text] [Related]
34. Epithelioid smooth muscle tumors of the uterus do not express CD1a: a potential immunohistochemical adjunct in their distinction from uterine perivascular epithelioid cell tumors. Fadare O; Liang SX Ann Diagn Pathol; 2008 Dec; 12(6):401-5. PubMed ID: 18995203 [TBL] [Abstract][Full Text] [Related]
35. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential. Ip PP; Cheung AN Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):691-704. PubMed ID: 21865091 [TBL] [Abstract][Full Text] [Related]
36. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas. Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786 [TBL] [Abstract][Full Text] [Related]
37. Epithelioid Leiomyosarcoma of the Uterus: Modern Outcome-based Appraisal of Diagnostic Criteria in a Large Institutional Series. Chapel DB; Nucci MR; Quade BJ; Parra-Herran C Am J Surg Pathol; 2022 Apr; 46(4):464-475. PubMed ID: 34419987 [TBL] [Abstract][Full Text] [Related]
38. Unusual types of smooth muscle tumors of uterine corpus: case reports and literature review. Makharoblidze E; Goishvili N; Mchedlishvili M; Khakhutaishvili I; Jangavadze M Georgian Med News; 2013 Mar; (216):7-11. PubMed ID: 23567300 [TBL] [Abstract][Full Text] [Related]
39. Smooth Muscle Tumors of the Visceral Adnexal and Uterine Ligaments and Adnexal Connective Tissue: A Clinicopathologic Study of 67 Cases. Patel V; Xing D; Feely M; Schoolmeester JK Int J Gynecol Pathol; 2020 Jan; 39(1):55-67. PubMed ID: 30702465 [TBL] [Abstract][Full Text] [Related]
40. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors. Esposito NN; Hunt JL; Bakker A; Jones MW Am J Surg Pathol; 2006 Jan; 30(1):97-103. PubMed ID: 16330948 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]